期刊文献+

TAG1抗原HLA-A2限制性表位预测及Hsp70融合蛋白的表达纯化

Prediction of HLA-A2 restricted cytotoxic T lymphocyte epitopes of TAG1 and expression and purification of fusion proteins of these epitopes and Hsp70
下载PDF
导出
摘要 目的:对在恶性黑素瘤(MM)组织中表达率极高并具有强免疫原性的新型睾丸肿瘤(C/T)抗原TAG1表位的HLAA2限制性细胞毒性T淋巴细胞(CTL)表位进行预测,并表达、纯化所预测表位与热休克蛋白70(Hsp70)融合蛋白,为特异性主动免疫治疗MM打下物质基础.方法:利用SYFPEITHI法和多项式方案结合预测TAG1的HLAA2限制性CTL表位,并将预测所得表位基因片断双串连后进行生物合成,克隆入带有GST标签并含Hsp70基因的原核表达载体,在IPTG诱导表达后,用GST蛋白纯化系统纯化.结果:预测并得到了三个TAG1的HLAA2限制性表位,成功地构建了表位与Hsp70的原核表达质粒(PGEXbwHSP70);表达和纯化得到了三个表位与Hsp70的可溶性融合蛋白.结论:成功获得三个预测表位与Hsp70的融合蛋白,为进一步研究其免疫功能、研制TAG1对MM的特异性治疗肽疫苗奠定了基础. AIM: To predict HLA-A2 restricted cytotoxic T lymphocyte (CTL) epitopes of the novel cancer/testis antigen TAG1 and to express and purify the fusion proteins of these epitopes and Hsp70 in prokaryotic system. METHODS: Long-distance prediction system SYFPEITHI and polynomial method were used to predict the HLA-A2 restricted CTL epitopes of TAG1. The epitopes were then cloned into the expression vector after synthesizing and annealing the nucleotide sequences of these epitopes. After induced with IPTG, the expressed fusion proteins were purified with GSTrap FF column. RESULTS: Three HLA-A2 restricted CTL epitopes of TAG1 were selected. The fusion genes PGEX-bw-Hsp70 were constructed and the fusion proteins were acquired successfully. CONCLUSION: The fusion proteins of Hsp70 and three HLA-A2 restricted CTL epitopes are expressed and purified successfully, which will be helpful in studying their immune functions and develop new peptide vaccines of malignant melanoma.
出处 《第四军医大学学报》 北大核心 2005年第20期1865-1867,共3页 Journal of the Fourth Military Medical University
关键词 睾丸肿瘤 抗原 肿瘤 TAGI 热休克蛋白70 表位 多项式方案 testicular neoplasms antigens, neoplasms Heat Shock proteins 70 TAG] Epitopes polynomial method
  • 相关文献

参考文献9

  • 1Hogan KT, Coppola MA, Gatlin CL, et al. Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma [J]. Cancer Res, 2004;64(2):1157-1163.
  • 2Lussow AR, Barrios C, van EJ, et al. Mycobacterial heat-shock proteins as carrier molecules [J]. Eur J Immunol, 1991;21(10):2297-2302.
  • 3Rammensee HG, Bachmann J, Emmerich NPN, et al. SYFPEITHI: database for MHC ligands and peptide motifs [J]. Immunogenetics, 1999;50(11):213-219.
  • 4Gulukota K, Sidney J , Sette A , et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules [J]. J Mol Biol, 1997;267(5):1258-1267.
  • 5董海龙,隋延仿,叶菁,李增山,曲萍,张秀敏,陈广生,禄韶英.肿瘤抗原MAGE-n HLA-A2限制性细胞毒性T细胞表位的预测及合成鉴定[J].中华医学杂志,2003,83(12):1080-1083. 被引量:10
  • 6肖露露,陈洪涛,叶欣,马琳雅,谭茵,张升.HLA多态性在广东汉族人群分布的特殊性[J].中华微生物学和免疫学杂志,1999,19(4):302-305. 被引量:31
  • 7Chiara C, Licia R, Francesca R, et al. Heat shock proteins: Biological functions and clinical application as personalized vaccines for human cancer [J]. Cancer Immunol Immunother, 2004;53(3): 227-233.
  • 8Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specically activate anti-melanoma T cells [J]. Cancer Res, 2001;61(1):222-227.
  • 9Ye J, Chen GS, Song HP, et al. Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo [J]. Cancer Immunol Immunother, 2004;53(9): 825-834.

二级参考文献16

  • 1肖露露 张升 等.高分辨率HLA-Ⅰ、Ⅱ类抗原一步分型新方法[J].中华微生物学和免疫学杂志,1997,17:148-148.
  • 2Boon T, Van Pel A. T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by trascription and translation of short subgenic regions. A hypothesis. Immuno Genetics,1989, 29:75-79.
  • 3Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3A1 peptide-plused mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage Ⅳ melanoma. J Exp Med, 1999, 190:1669-1678.
  • 4Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol, 2002, 38:158-164.
  • 5Rammensee HG, Bachmann J, Emmerich NPN, et al. SYFPEITHI:database for MHC ligands and peptide motifs. Immunogenetics,1999,50:213-219.
  • 6Gulukota K, Sidney J, Sette A, et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol, 1997, 267:1258-1267.
  • 7Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA- A*0201 epitope identified by mass spectrometry. Cancer Res, 2001,61: 4072-4077.
  • 8Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol, 1998, 59:1-14.
  • 9van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol, 1994, 24:3038-3043.
  • 10Falk K, Rotzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature, 1991,351: 290-296.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部